Concord Biotech Limited has secured approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Tofacitinib Tablets, 5 mg and 10 mg. Concord Biotech announced the regulatory clearance on June 10, 2026 through a filing to the National Stock Exchange and BSE Limited under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements, 2015.
Tofacitinib tablets are indicated for adult patients with moderately to severely active rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, moderately to severely active ulcerative colitis, and active polyarticular course juvenile idiopathic arthritis. Tofacitinib is a Janus kinase inhibitor prescribed for these chronic inflammatory and autoimmune conditions.
According to available market estimates, the combined U.S. market for Tofacitinib Tablets across both 5 mg and 10 mg strengths is approximately US$ 500 million.
The ANDA approval supports Concord Biotech's growth strategy and strengthens its presence in the U.S. pharmaceutical market. Concord Biotech's regulatory filing noted that the clearance would help it strengthen its product offerings in the U.S. generics segment.
Concord Biotech stated that the approval positions it to capitalise on the market opportunity, broaden its product portfolio, and support its long-term growth plans across U.S. and international markets. Concord Biotech continues to expand its pipeline of abbreviated new drug applications targeting regulated markets overseas including the United States.
Disclaimer: This article is based on company filings submitted to the Bombay Stock Exchange (BSE) and National Stock Exchange of India (NSE) and is for informational purposes only. It does not constitute investment advice or a recommendation. Investors should conduct their own research and consult a qualified financial advisor before making investment decisions.